T1	Participants 268 280	236 patients
T2	Participants 576 829	71 patients (1981-1983) compared the association of CYC with corticosteroids (CS) and PE to CS and PE, in order to evaluate the efficacy of CYC given as the first-line treatment to control disease activity and subsequent survival of PAN and CSS patients
T3	Participants 831 997	Between December 1983 and December 1988, we conducted two trials simultaneously: one aimed at patients without HBV markers and the second at patients with HBV markers
T4	Participants 1002 1033	78 patients without HBV markers
T5	Participants 1124 1159	33 patients with PAN related to HBV
T6	Participants 1442 1536	the last protocol including 56 patients and addressed to severe PAN without HBV markers or CSS
